Inhibition of Mutated BRAF in Melanoma.

被引：0
|
作者：
Kim, Taegyun [1 ]
Kim, Jihyun [1 ]
Lee, Min-Geol [1 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 363卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2261 / 2261
页数：1
相关论文
共 50 条
  • [31] Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.
    McArthur, Grant A.
    Callahan, Jason
    Ribas, Antoni
    Gonzalez, Rene
    Pavlick, Anna C.
    Hamid, Omid
    Gajewski, Thomas
    Puzanov, Igor
    Daud, Adil
    Yin, Ming
    Choong, Nicholas
    Shah, Jinay K.
    Fredrickson, Jill
    Hicks, Rodney J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Vemurafenib to eliminate BRAF-mutated circulating epithelial tumor cells (CETCs) from blood of patients with malignant melanoma.
    Zimon, Dorothea
    Pizon, Monika
    Stein, Ernst-Ludwig
    Pachmann, Ulrich A.
    Pachmann, Katharina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
    Alain P. Algazi
    Megan Othus
    Adil I. Daud
    Roger S. Lo
    Janice M. Mehnert
    Thach-Giao Truong
    Robert Conry
    Kari Kendra
    Gary C. Doolittle
    Joseph I. Clark
    Michael J. Messino
    Dennis F. Moore
    Christopher Lao
    Bryan A. Faller
    Rangaswamy Govindarajan
    Amy Harker-Murray
    Luke Dreisbach
    James Moon
    Kenneth F. Grossmann
    Antoni Ribas
    Nature Medicine, 2020, 26 : 1564 - 1568
  • [34] BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.
    Rohlfs, Michelle
    Bassett, Roland L.
    Lacey, Carol
    McQuail, Natalie
    Mehta, Urvi
    John, Ida
    Simien, Rinata
    Tupue, Stephanie
    Dett, Tina Karin
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Tawbi, Hussein Abdul-Hassan
    Davies, Michael A.
    Hwu, Wen-Jen
    Hwu, Patrick
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] BRAF Inhibition for metastatic Melanoma
    Hauschild, A.
    HNO, 2019, 67 (04) : 238 - 238
  • [36] BRAF and MEK inhibition in melanoma
    Dossett, Lesly A.
    Kudchadkar, Ragini R.
    Zager, Jonathan S.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 559 - 570
  • [37] Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma
    Amann, V. C.
    Hoffmann, D.
    Mangana, J.
    Dummer, R.
    Goldinger, S. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1638 - 1640
  • [38] Vemurafenib Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies
    Sharma, Anant
    Shah, Sachin R.
    Illum, Henrik
    Dowell, Jonathan
    DRUGS, 2012, 72 (17) : 2207 - 2222
  • [39] Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib.
    Gogas, Helen
    Schadendorf, Dirk
    Dummer, Reinhard
    Garbe, Claus
    Lebbe, Celeste
    Nathan, Paul D.
    Larkin, James M. G.
    Haydon, Andrew Mark
    Bafaloukos, Dimitris
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Efficacy and toxicity of BRAF targeted therapy in elderly patients with melanoma.
    Stoff, Ronen
    Markovic, Svetomir
    McWilliams, Robert R.
    Kottschade, Lisa A.
    Montane, Heather N.
    Dimou, Anastasios
    Dudek, Arkadiusz Z.
    Yan, Yiyi
    Tan, Winston
    Dronca, Roxana Stefania
    Seetharam, Mahesh
    Chen, Ruqin
    Block, Matthew Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345